Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
0.9194
+0.0340 (3.84%)
At close: Aug 20, 2026, 4:00 PM EDT
0.9194
0.00 (0.00%)
After-hours: Aug 20, 2026, 4:35 PM EDT
Akebia Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 219.06 | 236.2 | 160.18 | 194.62 | 292.48 | 211.65 | |
Revenue Growth | 7.52% | 47.46% | -17.70% | -33.46% | 38.19% | -28.17% |
Cost of Revenue | 40.69 | 40.35 | 26.15 | 39.76 | 22.5 | 81.49 |
Gross Profit | 178.37 | 195.84 | 134.03 | 154.86 | 269.99 | 130.16 |
Selling, General & Admin | 113.79 | 107.48 | 106.55 | 100.23 | 138.6 | 174.14 |
Research & Development | 70.46 | 62.36 | 37.65 | 63.08 | 129.99 | 147.85 |
Amortization of Goodwill & Intangibles | - | - | 36.04 | 36.04 | 36.04 | 36.04 |
Operating Expenses | 184.25 | 169.84 | 180.24 | 199.35 | 304.63 | 358.03 |
Operating Income | -5.88 | 26 | -46.21 | -44.5 | -34.64 | -227.88 |
Interest Expense | -17.34 | -24.18 | -18.19 | -6.03 | -15.69 | -20.02 |
Interest & Investment Income | - | - | - | - | - | 0.07 |
Other Non Operating Income (Expenses) | 4.62 | -3.04 | -0.24 | 0.89 | 3.15 | 2.41 |
EBT Excluding Unusual Items | -18.6 | -1.22 | -64.63 | -49.64 | -47.18 | -245.42 |
Merger & Restructuring Charges | -1.95 | - | -0.06 | -0.18 | -15.93 | -21.58 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.02 |
Asset Writedown | -7.31 | -2.51 | -4.21 | -1.58 | -30.24 | -15.05 |
Other Unusual Items | - | - | -0.52 | -0.52 | -0.87 | - |
Pretax Income | -27.85 | -3.72 | -69.41 | -51.93 | -94.23 | -282.02 |
Income Tax Expense | 1.82 | 1.62 | - | - | - | - |
Net Income | -29.67 | -5.35 | -69.41 | -51.93 | -94.23 | -282.02 |
Net Income to Common | -29.67 | -5.35 | -69.41 | -51.93 | -94.23 | -282.02 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 267 | 257 | 211 | 187 | 183 | 166 |
Shares Outstanding (Diluted) | 267 | 257 | 211 | 187 | 183 | 166 |
Shares Change | 15.07% | 21.91% | 12.53% | 2.56% | 10.14% | 19.85% |
EPS (Basic) | -0.11 | -0.02 | -0.33 | -0.28 | -0.52 | -1.70 |
EPS (Diluted) | -0.11 | -0.02 | -0.33 | -0.28 | -0.52 | -1.70 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 40.26 | 67.7 | -40.69 | -23.38 | -73.27 | -253.02 |
Free Cash Flow Per Share | 0.15 | 0.26 | -0.19 | -0.13 | -0.40 | -1.52 |
Gross Margin | 81.43% | 82.92% | 83.68% | 79.57% | 92.31% | 61.50% |
Operating Margin | -2.68% | 11.01% | -28.85% | -22.86% | -11.84% | -107.67% |
Profit Margin | -13.54% | -2.26% | -43.33% | -26.68% | -32.22% | -133.25% |
Free Cash Flow Margin | 18.38% | 28.66% | -25.40% | -12.02% | -25.05% | -119.55% |
EBITDA | -4.32 | 27.27 | -8.7 | -6.87 | 3.06 | -189.91 |
EBITDA Margin | -1.97% | 11.55% | -5.43% | -3.53% | 1.04% | -89.73% |
D&A For EBITDA | 1.55 | 1.27 | 37.5 | 37.63 | 37.7 | 37.97 |
EBIT | -5.88 | 26 | -46.21 | -44.5 | -34.64 | -227.88 |
EBIT Margin | -2.68% | 11.01% | -28.85% | -22.86% | -11.84% | -107.67% |
Revenue as Reported | 219.06 | 236.2 | 160.18 | 194.62 | 292.48 | 211.65 |
Advertising Expenses | - | 7.6 | 4.6 | 1 | 6.7 | 8.2 |